ARTICLE | Company News
BioLineRx soars on HCV deal
January 25, 2012 12:28 AM UTC
BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) jumped $2.26 (69%) to $5.55 on Tuesday after Genoscience (Marseille, France) granted BioLineRx exclusive, worldwide rights to preclinical oral HCV compound ...